WO2006100059A1 - Process for the production of methylcobalamin - Google Patents

Process for the production of methylcobalamin Download PDF

Info

Publication number
WO2006100059A1
WO2006100059A1 PCT/EP2006/002635 EP2006002635W WO2006100059A1 WO 2006100059 A1 WO2006100059 A1 WO 2006100059A1 EP 2006002635 W EP2006002635 W EP 2006002635W WO 2006100059 A1 WO2006100059 A1 WO 2006100059A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylcobalamin
dimethyl carbonate
methylation
cyanocobalamin
production
Prior art date
Application number
PCT/EP2006/002635
Other languages
French (fr)
Inventor
Juan Sallares
Inés PETSCHEN
Xavier Camps
Original Assignee
Ferrer Internacional, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional, S.A. filed Critical Ferrer Internacional, S.A.
Priority to BRPI0609125-3A priority Critical patent/BRPI0609125A2/en
Priority to CA002600987A priority patent/CA2600987A1/en
Priority to MX2007011649A priority patent/MX2007011649A/en
Priority to AU2006226577A priority patent/AU2006226577A1/en
Priority to EP06723627A priority patent/EP1861415A1/en
Priority to JP2008502319A priority patent/JP2008534458A/en
Publication of WO2006100059A1 publication Critical patent/WO2006100059A1/en
Priority to IL185722A priority patent/IL185722A0/en
Priority to NO20075211A priority patent/NO20075211L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Definitions

  • the present invention relates to a new process for the production of methylcobalamin (I), a coenzyme type vitamin Bi 2 useful in the biosynthesis of methionine and widely employed in medicine for the management of peripheral nervous system diseases.
  • Japanese Patent 45038059 discloses the preparation of methylcobalamin (I) by reduction methylation of cyanocobalamin (II) with methyl iodide and sodium borohydride, in the presence of iron salts and the resulting cyano ion is removed.
  • German Patent 2,058,892 discloses the preparation of methylcobalamin (I) by methylation of cyanocobalamin reduced with sodium borohydride through methyl p-toluenesulphonate .
  • the reaction occurs in the presence of metallic salts (copper or iron) which result in stable complexes with the cyano ion and in the absence of oxygen and light.
  • German Patent 2,149,150 discloses the preparation of methylcobalamin (I) by methylation of hydroxocobalamin (II) with methyl mercuric iodide [MeHgI] or ammonium methylhexafluorosilicate [ (NH 4 )SiF 6 Me] .
  • German Patent 2,255,203 discloses the preparation of methylcobalamin (I) by methylation and reduction of hydroxocobalamin (III) through oxalic acid methyl monoester and powdered Zn, in the presence of cobalt salts that catalyze the reaction.
  • German Patent 2,434,967 discloses the preparation of methylcobalamin (I) by methylation and reduction of cyanocobalamin (II) through methyl acid oxalate and powdered Zn, in the presence of cobalt salts that catalyze the reaction.
  • Belgian Patent 889,787 discloses the preparation of methylcobalamin (I) by methylation with methyl iodide after reducing cyanocobalamin (II) with sodium borohydride; the reaction occurs in the presence of an aldehyde in order to sequester the released cyano ion.
  • European Patent 1236737 discloses the preparation of methylcobalamin by reduction methylation of cyanocobalamin or hydroxocobalamin through sodium borohydride and trimethylsulfonium or trimethylsulfoxonium halides in the presence of iron or cobalt salts.
  • dimethylsulfoxide as a by-product can also occur, which, although non toxic, is not easily removed from the aqueous phase because of its high solubility and high boiling point (189°C) .
  • 189°C high boiling point
  • the present invention provides a new process for the production of methylcobalamin (I) that comprises using dimethyl carbonate (IV), a non-toxic and environment-friendly reagent, as a methylating agent.
  • dimethyl carbonate has arisen as a methylating agent in organic chemistry, especially in the field of the so-called green or sustainable chemistry.
  • the advantages of dimethyl carbonate are its innocuousness, low commercial cost and the formation of only carbon dioxide and methanol as by-products.
  • dimethyl carbonate due to its poor reactivity and insolubility in water, dimethyl carbonate usually requires anhydrous and vigorous conditions. Working conditions are usually at high temperatures and in strongly basic media.
  • dimethyl carbonate despite being an insoluble reagent in water (Merck Index, 13th Edition, #6065), has proved to be an excellent methylating agent of cobalamin Co 1 reduced form (B 12s ) obtained by reduction of either cyanocobalamin (II) or hydroxocobalamin (III) . That is why the so-called supernucleophilic Bi 2s anion is known to be one of the most powerful nucleophilic reagents in organic chemistry (N.N. Greenwood and A. Earnshaw, Chemistry of the elements, Pergamon Press, Oxford, England, 1984, pp. 1321-1322) .
  • a major embodiment of the present invention is the production of methylcobalamin (I) by reduction of cyanocobalamin (II) or hydroxocobalamin (III), and subsequent methylation with dimethyl carbonate (IV) :
  • R CN : Cyanocobalamin (II)
  • R OH : Hydroxocobalamin (III)
  • the contribution of the present invention is therefore based on the preparation of methylcobalamin with dimethyl carbonate under non-anhydrous mild conditions, which allow the reaction to be carried out under very selective conditions.
  • the methylation reaction occurs in the presence of a reducing agent (V) , in aqueous medium, with or without an organic co-solvent, at nearly ambient temperatures and in slightly basic medium.
  • V reducing agent
  • methylcobalamin is obtained with a good yield and quality.
  • the methylation with dimethyl carbonate does not form byproducts that may give rise to safety, toxicity or environmental problems.
  • the amount to be used of dimethyl carbonate can range from 1 to 25 equivalents, but preferably from 3 to 15 equivalents.
  • reducing agents (V) those which are capable of reducing the atom of Co(III) to Co(I) can be used, specially hydrides and more specially sodium borohydride .
  • the amount to be used of reducing agent (V) is not critical but from 4 to 25 equivalents, preferably from 10 to 20 equivalents are generally employed.
  • the reaction temperature can range from 5 to 60 0 C, but a temperature from 20 to 40°C is recommended.
  • reaction is carried out in the presence of sequestering agents of cyano ion under standard conditions described in the literature.
  • Specially efficient is the use of iron salts, such as ferrous sulfate, and cobalt salts, such as cobalt chloride (II) .
  • the amount to be used of sequestering agent of cyano ion is small, usually in the range between 0.1 and 1.0 equivalents, but preferably between 0.2 and 0.5 equivalents.
  • the reaction can be carried out by adding sequentially or simultaneously the respective solutions of reducing agent and dimethyl carbonate under the aforesaid conditions.
  • the reaction is carried out in aqueous or aqueous- organic medium.
  • an organic solvent If an organic solvent is used, its polarity should be enough as to attain solubilization in the aqueous reaction medium.
  • alcohols, ketones, ethers, esters, nitriles, amides and ureas preferably alcohols and lower ketones are useful.
  • Ci - C ⁇ -alcohols such as methanol, ethanol, n-propanol, i-propanol; ketones such as acetone and methyl ethyl ketone; ethers such as tetrahydrofurane and dioxane; acetonitrile and dimethylformamide.
  • reaction is carried out in the absence of oxygen and light in order to avoid the photo-oxidative degradation of methylcobalamin (R. J. Anderson, et al., Journal of Organic Chemistry 1992, 437, 227-337).

Abstract

The present invention relates to a new process for the production of methylcobalamin that comprises the methylation of cyanocobalamin or hydroxocobalamin with dimethyl carbonate in the presence of a reducing agent.

Description

PROCESS FOR THE PRODUCTION OF METHYLCOBAIAMIN
Field of the invention The present invention relates to a new process for the production of methylcobalamin (I), a coenzyme type vitamin Bi2 useful in the biosynthesis of methionine and widely employed in medicine for the management of peripheral nervous system diseases.
Background of the invention
Japanese Patent 45038059 discloses the preparation of methylcobalamin (I) by reduction methylation of cyanocobalamin (II) with methyl iodide and sodium borohydride, in the presence of iron salts and the resulting cyano ion is removed.
German Patent 2,058,892 (Offen.) discloses the preparation of methylcobalamin (I) by methylation of cyanocobalamin reduced with sodium borohydride through methyl p-toluenesulphonate . The reaction occurs in the presence of metallic salts (copper or iron) which result in stable complexes with the cyano ion and in the absence of oxygen and light.
German Patent 2,149,150 (Offen.) discloses the preparation of methylcobalamin (I) by methylation of hydroxocobalamin (II) with methyl mercuric iodide [MeHgI] or ammonium methylhexafluorosilicate [ (NH4)SiF6Me] .
German Patent 2,255,203 (Offen.) discloses the preparation of methylcobalamin (I) by methylation and reduction of hydroxocobalamin (III) through oxalic acid methyl monoester and powdered Zn, in the presence of cobalt salts that catalyze the reaction.
German Patent 2,434,967 (Offen.) discloses the preparation of methylcobalamin (I) by methylation and reduction of cyanocobalamin (II) through methyl acid oxalate and powdered Zn, in the presence of cobalt salts that catalyze the reaction.
Belgian Patent 889,787 discloses the preparation of methylcobalamin (I) by methylation with methyl iodide after reducing cyanocobalamin (II) with sodium borohydride; the reaction occurs in the presence of an aldehyde in order to sequester the released cyano ion.
European Patent 1236737 discloses the preparation of methylcobalamin by reduction methylation of cyanocobalamin or hydroxocobalamin through sodium borohydride and trimethylsulfonium or trimethylsulfoxonium halides in the presence of iron or cobalt salts.
All of these processes have several disadvantages because of using either commercially unavailable reagents (oxalic acid monoesters, ammonium methylhexafluorosilicate) or toxic reagents (methyl iodide, methyl p-toluenesulfonate) or environment- unfriendly reagents (methyl mercuric iodide) . Methylation with trimethylsulfonium or trimethylsulfoxonium halides produces dimethyl sulfur as a by-product, which is deleterious and stinking. The formation of dimethylsulfoxide as a by-product can also occur, which, although non toxic, is not easily removed from the aqueous phase because of its high solubility and high boiling point (189°C) . In conclusion, an industrial process for the production of methylcobalamin that employs a non-toxic and/or environment-friendly methylating agent is not currently available.
Description of the invention
The present invention provides a new process for the production of methylcobalamin (I) that comprises using dimethyl carbonate (IV), a non-toxic and environment-friendly reagent, as a methylating agent.
O
MeO- OMe IV
In recent years dimethyl carbonate has arisen as a methylating agent in organic chemistry, especially in the field of the so-called green or sustainable chemistry. The advantages of dimethyl carbonate are its innocuousness, low commercial cost and the formation of only carbon dioxide and methanol as by-products. However, due to its poor reactivity and insolubility in water, dimethyl carbonate usually requires anhydrous and vigorous conditions. Working conditions are usually at high temperatures and in strongly basic media.
In the present invention, dimethyl carbonate, despite being an insoluble reagent in water (Merck Index, 13th Edition, #6065), has proved to be an excellent methylating agent of cobalamin Co1 reduced form (B12s) obtained by reduction of either cyanocobalamin (II) or hydroxocobalamin (III) . That is why the so-called supernucleophilic Bi2s anion is known to be one of the most powerful nucleophilic reagents in organic chemistry (N.N. Greenwood and A. Earnshaw, Chemistry of the elements, Pergamon Press, Oxford, England, 1984, pp. 1321-1322) .
In fact, the aforesaid nucleophilic form Co1 (Bi23) results from the reduction of cobalamin Bi2 according to the following scheme (D. Autisser et al., Bull. Soc. Chim. France 1980, part 2, 192) :
CN Co (III) + e" Co (II) + e~ Co (I)
- CN
312 B 12 r B12 !
and, later, from the nucleophilic attack of Bi2s on the methyl group of dimethyl carbonate, methylcobalamin is obtained.
Consequently, a major embodiment of the present invention is the production of methylcobalamin (I) by reduction of cyanocobalamin (II) or hydroxocobalamin (III), and subsequent methylation with dimethyl carbonate (IV) :
Figure imgf000006_0001
R R = CN : Cyanocobalamin (II) R = OH : Hydroxocobalamin (III)
R
R= CH3 : Methylcobalamin (I)
R
The contribution of the present invention is therefore based on the preparation of methylcobalamin with dimethyl carbonate under non-anhydrous mild conditions, which allow the reaction to be carried out under very selective conditions.
As a matter of fact the methylation reaction occurs in the presence of a reducing agent (V) , in aqueous medium, with or without an organic co-solvent, at nearly ambient temperatures and in slightly basic medium.
Under these conditions, methylcobalamin is obtained with a good yield and quality. Moreover, the methylation with dimethyl carbonate does not form byproducts that may give rise to safety, toxicity or environmental problems. The amount to be used of dimethyl carbonate can range from 1 to 25 equivalents, but preferably from 3 to 15 equivalents.
As reducing agents (V) , those which are capable of reducing the atom of Co(III) to Co(I) can be used, specially hydrides and more specially sodium borohydride .
The amount to be used of reducing agent (V) is not critical but from 4 to 25 equivalents, preferably from 10 to 20 equivalents are generally employed. The reaction temperature can range from 5 to 600C, but a temperature from 20 to 40°C is recommended.
The reaction is carried out in the presence of sequestering agents of cyano ion under standard conditions described in the literature. Specially efficient is the use of iron salts, such as ferrous sulfate, and cobalt salts, such as cobalt chloride (II) .
The amount to be used of sequestering agent of cyano ion is small, usually in the range between 0.1 and 1.0 equivalents, but preferably between 0.2 and 0.5 equivalents.
The reaction can be carried out by adding sequentially or simultaneously the respective solutions of reducing agent and dimethyl carbonate under the aforesaid conditions. The reaction is carried out in aqueous or aqueous- organic medium. If an organic solvent is used, its polarity should be enough as to attain solubilization in the aqueous reaction medium. For example, alcohols, ketones, ethers, esters, nitriles, amides and ureas; preferably alcohols and lower ketones are useful. Preferred solvents are Ci - Cή-alcohols such as methanol, ethanol, n-propanol, i-propanol; ketones such as acetone and methyl ethyl ketone; ethers such as tetrahydrofurane and dioxane; acetonitrile and dimethylformamide.
The reaction is carried out in the absence of oxygen and light in order to avoid the photo-oxidative degradation of methylcobalamin (R. J. Anderson, et al., Journal of Organic Chemistry 1992, 437, 227-337).
The present invention will now be described in detail by the following non-limiting examples.
Example 1 : Methylcobalamin (I)
To a stirred mixture of 10 g (0.0074 mole) of cyanocobalamin, 0.65 g (0.0027 mole) of cobalt chloride (II) hexahydrate, 6.65 g (0.075 mole) of dimethyl carbonate in 125 ml of water at 35-400C, in inert atmosphere and red light was added over a period of 2 hours a solution of 4.2 g (0.11 mole) of sodium borohydride and 0.42 g of IN sodium hydroxide in 25 ml of water. After stirring for 4 hours at the same temperature, the mixture was cooled at 100C, stirred for further 3 hours and then filtered. The solid obtained was treated with 200 mL of acetone/water (60:40 v/v) and filtered. The resultant solution was concentrated at reduced pressure until the acetone was removed. The aqueous solution was chromatographied through 500 ml of a non-polar resin (Amberlite XAD-2). All the inorganic salts were removed by washing first with water until constant conductivity, and then eluting the methylcobalamin with a mixture of methanol/water (50:50 v/v) . The eluate with the pure product was concentrated at reduced pressure and then precipitated with 10 volumes of acetone to give 8.4 g (85%). UV spectrum, solution pH 2.0: maximum absorption at 262-266, 303-307 and 459-463 nm.
UV spectrum, solution pH 7.0: maximum absorption at 265-269, 340-344 and 520-524 nm. Purity by chromatographic assay (HPLC) was > 99%.
Example 2 : Methylcobalamin (I)
To a solution of 13 g (0.0096 mole) of cyanocobalamin was added 0.91 g (0.0038 mole) of cobalt chloride (II) hexahydrate in 169 ml of water. The mixture was heated at 35-37 °C, and under nitrogen atmosphere and protected from light a solution of 4.75 g (0.053 mole) of dimethyl carbonate in 13 ml of methyl ethyl ketone and a solution of 5.2 g (0.138 mole) of sodium borohydride in 26 ml of water containing 0.26 ml of 2N sodium hydroxide were simultaneously added over a period of 3 hours. After stirring for 1 hour at 35-37°C, the mixture was cooled at 12°C, stirred for an additional 3 hours and filtered. The solid obtained was treated with 182 mL of acetone/water (50:50 v/v) at 35-40°C, filtered and the resultant solution was concentrated at reduced pressure until the acetone was removed. The aqueous solution was chromatographied through 500 ml of a non-polar resin
(Diaion HP20L) . All the inorganic salts were removed by washing first with water until constant conductivity, and then eluting the methylcobalamin with a mixture of methanol/water (50:50 v/v). The fraction with the pure product was concentrated at reduced pressure and then precipitated with 10 volumes of acetone to give 11.6 g
(90%) .

Claims

1. A process for the production of methylcobalamin that comprises the methylation of cyanocobalamin or hydroxocobalamin with dimethyl carbonate in the presence of a reducing agent.
2. A process according to claim 1 wherein the methylation occurs in the presence of a sequestering agent of cyano ion in an aqueous or hydro-organic medium.
3. A process according to claim 1 or 2 wherein the reducing agent is sodium borohydride.
4. A process according to any one of claims 1 to 3, wherein the sequestering agent is iron sulfate (II) or cobalt chloride (II) .
5. A process according to any one of claims 1 to 4 wherein the reaction occurs by adding sequentially or simultaneously sodium borohydride and dimethyl carbonate .
PCT/EP2006/002635 2005-03-23 2006-03-22 Process for the production of methylcobalamin WO2006100059A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0609125-3A BRPI0609125A2 (en) 2005-03-23 2006-03-22 process for the production of methylcobalamin
CA002600987A CA2600987A1 (en) 2005-03-23 2006-03-22 Process for the production of methylcobalamin
MX2007011649A MX2007011649A (en) 2005-03-23 2006-03-22 Process for the production of methylcobalamin.
AU2006226577A AU2006226577A1 (en) 2005-03-23 2006-03-22 Process for the production of methylcobalamin
EP06723627A EP1861415A1 (en) 2005-03-23 2006-03-22 Process for the production of methylcobalamin
JP2008502319A JP2008534458A (en) 2005-03-23 2006-03-22 Method for producing methylcobalamin
IL185722A IL185722A0 (en) 2005-03-23 2007-09-04 Process for the production of methylcobalamin
NO20075211A NO20075211L (en) 2005-03-23 2007-10-11 Methods for preparing methylcobalamin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200500703A ES2264374B1 (en) 2005-03-23 2005-03-23 METHODCOBALAMINE MANUFACTURING PROCEDURE.
ES200500703 2005-03-23

Publications (1)

Publication Number Publication Date
WO2006100059A1 true WO2006100059A1 (en) 2006-09-28

Family

ID=36304703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002635 WO2006100059A1 (en) 2005-03-23 2006-03-22 Process for the production of methylcobalamin

Country Status (16)

Country Link
EP (1) EP1861415A1 (en)
JP (1) JP2008534458A (en)
KR (1) KR20070106791A (en)
CN (1) CN101175764A (en)
AR (1) AR053558A1 (en)
AU (1) AU2006226577A1 (en)
BR (1) BRPI0609125A2 (en)
CA (1) CA2600987A1 (en)
ES (1) ES2264374B1 (en)
IL (1) IL185722A0 (en)
MX (1) MX2007011649A (en)
NO (1) NO20075211L (en)
RU (1) RU2007139143A (en)
TW (1) TW200700430A (en)
UY (1) UY29432A1 (en)
WO (1) WO2006100059A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391340A (en) * 2011-10-31 2012-03-28 河北玉星生物工程有限公司 Preparation method of mecobalamin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165934A1 (en) * 2011-05-30 2012-12-06 Interquim, S.A. De C.V. Methylcobalamin synthesis process
CN103113443B (en) * 2013-02-01 2015-02-11 山东省医药工业研究所 Novel chemical synthesis method for preparing mecobalamine
CN105218608A (en) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 A kind of preparation method of mecobalamin
CN108948116A (en) * 2018-08-30 2018-12-07 上海应用技术大学 A kind of green synthesis process of Mecobalamin
CN114874276A (en) * 2022-04-21 2022-08-09 南京工业大学 Improved method for synthesizing mecobalamin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236737A1 (en) * 1999-12-09 2002-09-04 Eisai Co., Ltd. Process for production of methylcobalamin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759614A (en) * 1969-12-01 1971-06-01 Glaxo Lab Ltd CYANIDE ION REMOVAL FROM CORRINOID SOLUTIONS
US3928320A (en) * 1971-11-10 1975-12-23 Jean Boige Process for the preparation of methylcobalamine
JP4358615B2 (en) * 2001-06-05 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing methylcobalamin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236737A1 (en) * 1999-12-09 2002-09-04 Eisai Co., Ltd. Process for production of methylcobalamin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391340A (en) * 2011-10-31 2012-03-28 河北玉星生物工程有限公司 Preparation method of mecobalamin

Also Published As

Publication number Publication date
CA2600987A1 (en) 2006-09-28
MX2007011649A (en) 2007-11-14
EP1861415A1 (en) 2007-12-05
IL185722A0 (en) 2008-01-06
AU2006226577A1 (en) 2006-09-28
RU2007139143A (en) 2009-04-27
BRPI0609125A2 (en) 2010-02-23
UY29432A1 (en) 2006-06-30
TW200700430A (en) 2007-01-01
AR053558A1 (en) 2007-05-09
JP2008534458A (en) 2008-08-28
KR20070106791A (en) 2007-11-05
ES2264374B1 (en) 2007-11-01
NO20075211L (en) 2007-10-11
CN101175764A (en) 2008-05-07
ES2264374A1 (en) 2006-12-16

Similar Documents

Publication Publication Date Title
WO2006100059A1 (en) Process for the production of methylcobalamin
EP2045257B1 (en) Process for producing di(pyrimidine nucleoside 5'-)polyphosphate
JP7373598B2 (en) Method for producing dinucleoside polyphosphate compounds
CN112194661B (en) Preparation method of 4-amino-7-iodopyrrolo [2, l-f ] [ l,2,4] triazine
KR100694688B1 (en) Process for production of methylcobalamin
CA3048549A1 (en) Method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
US20240018109A1 (en) Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
GB1572137A (en) Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
CA2795558A1 (en) Methods for synthesizing radiolabelled guanidine derivatives for use in positron emission tomography
JP4091135B2 (en) Process for producing substituted 3- (phenylimino) -3H-phenothiazines and phenoxazines
JP4358615B2 (en) Method for producing methylcobalamin
SK124893A3 (en) Method of preparation 3,7-dialkylxantines from 3-alkylxantines
KR940007418B1 (en) Process for the preparation of l-ascorbic acid 2-phosphat ester salt derivative
CN114249667B (en) Method for preparing N-H ketoamide by two-step one-pot reaction catalyzed by tert-butyl alcohol salt
CN110078669B (en) Green synthesis method of metronidazole and deuterated derivatives thereof
JP4870296B2 (en) Method for producing hinokitiol glycoside
ICHINO et al. Studies on the Structure of a New Type of Cyclonucleoside, 6, 2'-Triazacyclocytidine
Lee N-Hydroxypteridines structurally analogous to oncogenic N-hydroxypurine. Covalent hydration of 1-hydroxy-2-oxo-1, 2-dihydropteridine
KR100351743B1 (en) Process for preparation of the n,n-dicyclohexyl-2-benzothiazole sulfenamide
JPH0952855A (en) Production of 9-fluorenylmethanols
CN117561267A (en) Boric acid compound and method for producing same
KR20200106738A (en) New method of preparing for P1,P4-Di(Uridine 5'-)tetraphosphate, salt thereof or hydrate thereof
Krasnokutskaya et al. 4-Iodoantipyrine synthesized by means of solid-state mechanical activation
CN114846018A (en) Process for producing uridine 5' -diphosphate (UDP), salt thereof or hydrate thereof
CN109912673A (en) Cangrelor intermediate and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006226577

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 185722

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2600987

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200680009228.0

Country of ref document: CN

Ref document number: MX/a/2007/011649

Country of ref document: MX

Ref document number: 12007502071

Country of ref document: PH

Ref document number: 2006723627

Country of ref document: EP

Ref document number: 2008502319

Country of ref document: JP

Ref document number: 1020077021782

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006226577

Country of ref document: AU

Date of ref document: 20060322

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006226577

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3750/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007139143

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006723627

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609125

Country of ref document: BR

Kind code of ref document: A2